270 related articles for article (PubMed ID: 34138966)
1. Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions.
Goc A; Sumera W; Rath M; Niedzwiecki A
PLoS One; 2021; 16(6):e0253489. PubMed ID: 34138966
[TBL] [Abstract][Full Text] [Related]
2. Molecular Interactions of Tannic Acid with Proteins Associated with SARS-CoV-2 Infectivity.
Haddad M; Gaudreault R; Sasseville G; Nguyen PT; Wiebe H; Van De Ven T; Bourgault S; Mousseau N; Ramassamy C
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269785
[TBL] [Abstract][Full Text] [Related]
3. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
Muralidar S; Gopal G; Visaga Ambi S
J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis.
Bayati A; Kumar R; Francis V; McPherson PS
J Biol Chem; 2021; 296():100306. PubMed ID: 33476648
[TBL] [Abstract][Full Text] [Related]
5. Polyunsaturated ω-3 fatty acids inhibit ACE2-controlled SARS-CoV-2 binding and cellular entry.
Goc A; Niedzwiecki A; Rath M
Sci Rep; 2021 Mar; 11(1):5207. PubMed ID: 33664446
[TBL] [Abstract][Full Text] [Related]
6. Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.
Li J; Wang P; Tracey KJ; Wang H
Mol Med; 2021 May; 27(1):49. PubMed ID: 34022793
[TBL] [Abstract][Full Text] [Related]
7. Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies.
Jena AB; Kanungo N; Nayak V; Chainy GBN; Dandapat J
Sci Rep; 2021 Jan; 11(1):2043. PubMed ID: 33479401
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2.
Rowland R; Brandariz-Nuñez A
Microbiol Spectr; 2021 Oct; 9(2):e0119921. PubMed ID: 34494876
[TBL] [Abstract][Full Text] [Related]
9. Contribution of Syndecans to the Cellular Entry of SARS-CoV-2.
Hudák A; Letoha A; Szilák L; Letoha T
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069441
[TBL] [Abstract][Full Text] [Related]
10. "Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry.
Shukla SP; Cho KB; Rustagi V; Gao X; Fu X; Zhang SX; Guo B; Udugamasooriya DG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445669
[TBL] [Abstract][Full Text] [Related]
11. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
12. TMPRSS11D and TMPRSS13 Activate the SARS-CoV-2 Spike Protein.
Kishimoto M; Uemura K; Sanaki T; Sato A; Hall WW; Kariwa H; Orba Y; Sawa H; Sasaki M
Viruses; 2021 Feb; 13(3):. PubMed ID: 33671076
[TBL] [Abstract][Full Text] [Related]
13. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.
Tandon R; Sharp JS; Zhang F; Pomin VH; Ashpole NM; Mitra D; McCandless MG; Jin W; Liu H; Sharma P; Linhardt RJ
J Virol; 2021 Jan; 95(3):. PubMed ID: 33173010
[TBL] [Abstract][Full Text] [Related]
14. ACE-2-Derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2.
Panda SK; Sen Gupta PS; Biswal S; Ray AK; Rana MK
J Proteome Res; 2021 Feb; 20(2):1296-1303. PubMed ID: 33472369
[TBL] [Abstract][Full Text] [Related]
15. Identification of potent small molecule inhibitors of SARS-CoV-2 entry.
Mediouni S; Mou H; Otsuka Y; Jablonski JA; Adcock RS; Batra L; Chung DH; Rood C; de Vera IMS; Rahaim R; Ullah S; Yu X; Getmanenko YA; Kennedy NM; Wang C; Nguyen TT; Hull M; Chen E; Bannister TD; Baillargeon P; Scampavia L; Farzan M; Valente ST; Spicer TP
SLAS Discov; 2022 Jan; 27(1):8-19. PubMed ID: 35058179
[TBL] [Abstract][Full Text] [Related]
16. Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection
Curreli F; Victor SMB; Ahmed S; Drelich A; Tong X; Tseng CK; Hillyer CD; Debnath AK
mBio; 2020 Dec; 11(6):. PubMed ID: 33310780
[TBL] [Abstract][Full Text] [Related]
17. Significant Inactivation of SARS-CoV-2 In Vitro by a Green Tea Catechin, a Catechin-Derivative, and Black Tea Galloylated Theaflavins.
Ohgitani E; Shin-Ya M; Ichitani M; Kobayashi M; Takihara T; Kawamoto M; Kinugasa H; Mazda O
Molecules; 2021 Jun; 26(12):. PubMed ID: 34208050
[TBL] [Abstract][Full Text] [Related]
18. Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis.
Hou Y; Ge S; Li X; Wang C; He H; He L
Chem Biol Interact; 2021 Apr; 338():109420. PubMed ID: 33609497
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.
Seyedpour S; Khodaei B; Loghman AH; Seyedpour N; Kisomi MF; Balibegloo M; Nezamabadi SS; Gholami B; Saghazadeh A; Rezaei N
J Cell Physiol; 2021 Apr; 236(4):2364-2392. PubMed ID: 32901936
[TBL] [Abstract][Full Text] [Related]
20. An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2.
Williams-Noonan BJ; Todorova N; Kulkarni K; Aguilar MI; Yarovsky I
J Phys Chem B; 2021 Mar; 125(10):2533-2550. PubMed ID: 33657325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]